世界中医药
文章摘要
引用本文:谷丰1,杨巧宁2,白瑞娜2,郗瑞席2,董国菊2,李立志2,史大卓2.芪参益气滴丸治疗冠心病介入术后合并高血压患者的预后研究[J].世界中医药,2018,(10):.  
芪参益气滴丸治疗冠心病介入术后合并高血压患者的预后研究
Prognoses Study on Qishen Yiqi Dropping Pills in Treating Patients with Coronary Heart Disease and Hypertension after Percutaneous Coronary Intervention
投稿时间:2018-04-25  
DOI:10.3969/j.issn.1673-7202.2018.10.007
中文关键词:  芪参益气滴丸  冠心病  高血压  终点事件
English Keywords:Qishen Yiqi Dropping Pills  Coronary heart disease  Hypertension  Endpoints
基金项目:国家中医药行业科研专项(201007001)——中医药防治冠心病关键技术转化及应用研究
作者单位
谷丰1,杨巧宁2,白瑞娜2,郗瑞席2,董国菊2,李立志2,史大卓2 1 中国中医科学院西苑医院心功能科,北京,100091
2 中国中医科学院心血管病研究所,北京,100091 
摘要点击次数: 761
全文下载次数: 642
中文摘要:
      目的:观察芪参益气滴丸对冠心病介入术后合并高血压患者的疗效。方法:选取2010年10月至2013年04月全国11个省市40家三级西医、中医或中西医综合医院收治的冠心病介入术后合并高血压的患者960例,按照是否使用芪参益气滴丸分为对照组(n=474)和观察组(n=486),对照组给予西医常规药物治疗,观察组在常规治疗基础上加服芪参益气滴丸,0.5 g/次,3次/d。2组均治疗6个月,随访6个月。分别在入组时和治疗后1、3、6、12个月观察主要及次要终点事件的发生情况,同时观察血瘀证计分和西雅图心绞痛量表评分情况及不良事件发生情况。结果:随访6个月中,观察组患者终点事件发生率(主要,次要)方面,较对照组明显减少(P<0.05)。Kaplan-Meier生存函数估计显示,12月内观察组生存率优于对照组(P<0.05)。血瘀证计分方面,与本组入组时比较,2组在治疗1、3、6及12个月,血瘀证计分皆明显降低(P<0.05);在治疗6及12个月,观察组血瘀证计分明显低于对照组(P<0.05)。西雅图心绞痛量表评分方面,与本组入组时比较,2组在治疗1、3、6及12个月,西雅图心绞痛量表各维度评分皆明显升高(P<0.05);在治疗1、3、6及12个月,观察组的躯体受限程度方面明显高于对照组(P<0.05);在治疗1、3及12个月时,观察组的心绞痛发作情况方面明显高于对照组(P<0.05);在治疗12个月时,观察组的疾病认知程度方面明显高于对照组(P<0.05)。安全性方面,观察组未发生与本药物相关的不良反应。2组间不良事件发生率差异无统计学意义(P>0.05)。结论:芪参益气滴丸结合西医常规治疗冠心病介入术后合并高血压患者,可减少12个月内心血管终点事件的发生,提高12个月内患者的生存率,改善患者血瘀证计分和生命质量。
English Summary:
      To observe the efficacy of Qishen Yiqi Dropping Pills (QYDP) on patients with coronary heart disease (CHD) and hypertension after successful percutaneous coronary intervention (PCI).Methods:A total of 960 CHD patients with Hypertension after successful PCI treated from March 2015 to March 2017 were selected and divided into the control group (n=474) and the observation group (n=486) according to their treatment with or without QYDP.Patients in the control group were given conventional western medicine,while the patients in the observation group were given Qishen Yiqi Dropping Pills (0.5 g each time,3 times per day for half a year and 6-month follow-ups) on the basis of the same treatment.The primary and secondary endpoint events were observed at the time of enrollment and at 1,3,6,and 12 months after treatment,and the scores of the blood stasis syndrome and the Seattle angina scale and the occurrence of adverse events were observed.Results:The incidence of primary and secondary endpoints were obviously decreased in the observation group compared with the control group (P<0.05).Kaplan-Meier showed that the survival rate in the observation group was higher than in the control group during the 12 months observation (P<0.05).Compared with before treatment,scores for BSS was obviously decreased in the 2 groups at 1,3,6 and 12 months (P<0.05),which was decreased more obviously in the observation group than in the control group at 6 and 12 months of treatment (P<0.05).Compared with before treatment,score of SAQ was improved significantly in the observation and control groups at 1,3,6 and 12 months (P<0.05).The physical limitation of SAQ was improved more significantly in the observation group than in the control group at 1,3,6 and 12 months of the treatment (P<0.05).The angina frequency of SAQ increased more significantly in the observation group than in the control group at 1,3 and 12 months of treatment (P<0.05).The disease perception of SAQ improved more significantly in the observation group than in the control group at 12 months of treatment (P<0.05).There was no adverse reaction associated with this drug occurring in the observation group,and there were no statistical difference between the treatment and control groups in adverse events (P>0.05).Conclusion:QYDP combined conventional western medicine treatment could reduce the primary and secondary endpoints and improve survival rate and scores for BSS and SAQ of CHD patients complicated hypertension after PCI.
查看全文  查看/发表评论  下载PDF阅读器